Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05860803
Other study ID # 22-002736
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date December 1, 2026

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to investigate whether a home-based and health coach supported specific breathing and respiratory muscle training program improves the ability to exercise, the function of the lungs and breathing muscles, and general clinical status in people with non-cystic fibrosis bronchiectasis (non-CFB).


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 1, 2026
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Mayo Clinic patient with confirmed diagnosis of Non-Cystic Fibrosis Bronchiectasis (non-CFB): Non-CFB as confirmed by clinical history, including cough, shortness of breath, exertional dyspnea, pulmonary function tests, and high-resolution computed tomography. Patients will be considered clinically stable if there is no evidence of an exacerbation or change(s) in medical therapy in the previous three weeks. - Able and willing to provide informed consent to participate in the study. Exclusion Criteria: - Presence of significant coexisting disease, neurological conditions, and/or orthopedic complications that affect ability to undertake exercise. - Presence of advanced heart failure. - Current use of antibiotics. - Acute exacerbation(s) within 3-weeks prior to study commencement. - Participation within a pulmonary rehabilitation program within 6-months prior to study commencement.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LungTrainers
A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
Behavioral:
LungTrainers Pulmonary Rehabilitation regime
Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.

Locations

Country Name City State
United States Mayo Clinic Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in six-minute walk test distance Measures the distance walked in meters for 6 minutes. Baseline, 8 weeks
Primary Change in peak oxygen uptake during maximal incremental exercise test Maximum volume or amount of oxygen consumption during cardiopulmonary exercise test (treadmill or cycle). Baseline, 8 weeks
Secondary Change in exercise time during maximal incremental exercise test Maximum volume or amount of oxygen consumption during cardiopulmonary exercise test (treadmill or cycle). Baseline, 8 weeks
Secondary Peak exercise work rate during maximal incremental exercise test Highest work rate achieved during cardiopulmonary exercise test (treadmill or cycle) Baseline, 8 weeks
Secondary Change in forced vital capacity Measured by spirometry to determine the maximal amount of air that can be forcibly exhaled from the lungs after a full inhale, reported as liters (L). Baseline, 8 weeks
Secondary Change in forced expiratory volume in 1 second Measured by spirometry to determine the volume of air that can be exhaled in 1 second with a forced breath. Baseline, 8 weeks
Secondary Change in maximal voluntary ventilation Measured by spirometry to determine the largest amount of air inhaled and exhaled during maximal voluntary effort. Baseline, 8 weeks
Secondary Change in maximal inspiratory pressure Assessed using a calibrated pressure meter to evaluate inspiratory muscle strength. After exhaling slowly and maximally (i.e., to residual volume), the subject will be urged strongly to 'suck-in as maximally as possible' (Mueller maneuver) for approximately 3 to 5 seconds. Measured by 3-5 repetitions and defined as the highest value (in cmH2O) of three measurements that vary by =5%. Baseline, 8 weeks
Secondary Change in maximal expiratory mouth pressure Assessed using a calibrated pressure meter to evaluate expiratory muscle strength. After inhaling slowly and maximally (i.e., to total lung capacity), the patient will be strongly urged to 'blow-out as maximally as possible' (Valsalva maneuver) for approximately 3 to 5 seconds. Measured by 3-5 repetitions and defined as the highest value (in cmH2O) of three measurements that vary by =5%. Baseline, 8 weeks
Secondary Change in diaphragm thickness Ultrasound-derived diaphragm thickness, reported centimeters (cm) Baseline, 8 weeks
Secondary Change in diaphragm thickening fraction Ultrasound-derived diaphragm thickening fraction defined as ratio of at total lung capacity thickness at functional residual capacity to thickness at functional residual capacity, reported in millimeters (mm). Baseline, 8 weeks
Secondary Change in diaphragm excursion Ultrasound-derived diaphragm excursion defined as the amplitude of excursion from baseline to the point of maximum height during the sniff, reported in centimeters (cm). Baseline, 8 weeks
Secondary Change in Modified Medical Research Council Dyspnea Scale (mMRC) mMRC scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4 which 0=no breathlessness except on strenuous exercise; 1=shortness of breath when hurrying on the level or walking up a slight hill; 2=walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3=stops for breath after walking approximately 100 m or after few minutes on the level; and 4=too breathless to leave the house, or breathless when dressing or undressing. Baseline, 8 weeks
Secondary Change in St. George's Respiratory Questionnaire (SGRQ) SGRQ measures impact on overall health, daily life, and perceived well-being in patients with lung disease, specifically obstructive airways disease. The questionnaire consists of two parts with three components; Part 1: symptoms component (frequency & severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Scores range from 0 to 100, with higher scores indicating more limitations. Baseline, 8 weeks
Secondary Change in Dartmouth COOP Functional Assessment Charts The Dartmouth COOP chart consists of nine questions measuring seven domains of health status: physical fitness, feelings, daily activities, social activities, change in health status, current overall health perceptions, bodily pain, social support, and quality of life. Each question has five response options. Baseline, 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT01792440 - The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis N/A
Active, not recruiting NCT05523180 - A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life N/A
Completed NCT03218917 - Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis Phase 2
Completed NCT05495243 - Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough Phase 2
Recruiting NCT06237348 - Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH N/A
Completed NCT03056326 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Phase 1
Not yet recruiting NCT02614300 - The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis N/A
Recruiting NCT04322929 - Roflumilast in Non-CF Bronchiectasis Study (2019) Phase 2
Completed NCT05369624 - Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program N/A
Completed NCT04010799 - A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis Phase 1
Completed NCT03428334 - Roflumilast in Non-CF Bronchiectasis Study Phase 2
Recruiting NCT06164470 - Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis N/A
Completed NCT04656275 - A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation Phase 1
Not yet recruiting NCT06151366 - Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
Completed NCT02081963 - Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Phase 4
Completed NCT02883101 - The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis N/A
Completed NCT01792427 - Mortality in Non-cystic Fibrosis Bronchiectasis N/A
Recruiting NCT04278040 - Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis Phase 2
Active, not recruiting NCT05006573 - Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis Phase 3
Not yet recruiting NCT06352944 - Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children